| Ytd | -14.04% | |
| 1y | 132.85% |
| Open | 8.04 | Prev Close | 8.05 | Low | 7.80 | High | 8.22 | Mkt Cap | 491.23M |
| Vol | 723.89K | Avg Vol | 1.03M | EPS | -3.28 | P/E | -2.46 | Forward P/E | -1.00 |
| Beta | 1.93 | Short Ratio | 7.35 | Inst. Own | 76.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 8.03 | 200-d Avg | 8.31 | 1yr Est | 27.33 |
KYTX News
Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for auto
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSP
Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing
EMERYVILLE, Calif., and WALTHAM, Mass.
Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changi
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a po
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a l
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct f
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response
Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopha
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a la
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndr
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a la
Kyverna Therapeutics (NASDAQ: KYTX) highlighted new clinical data for its CD19-directed autologous C
Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability sco
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further i
Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) has earned a consensus recommendation of
EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq:
